Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 363.5 DKK -0.58% Market Closed
Market Cap: 90.3B DKK

P/E
Price to Earnings

11
Current
32
Median
21.4
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
11
=
Market Cap
86.6B DKK
/
Net Income
7.8B DKK
Earnings Growth PEG
DK
Genmab A/S
CSE:GMAB
Average P/E: 77.1
11
12%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 705.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.5
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.5
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
278
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -491.9 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -131.7 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
12.8
2-Years Forward
P/E
10.3
3-Years Forward
P/E
7.8